An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma.
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2018
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 20 Jun 2018 Status changed from active, no longer recruiting to completed.
- 26 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.